GMDA - Gamida Cell Ltd
Close
0.0327
-0.007 -22.324%
Share volume: 23,036,893
Last Updated: Fri 05 Apr 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.04
-0.01
-18.25%
Fundamental analysis
6%
Profitability
0%
Dept financing
12%
Liquidity
50%
Performance
0%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
0 0%
6 Months
0 0%
1 Year
0 0%
2 Year
0 0%
Key data
Company detail
CEO:
Region: US
Website: gamida-cell.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: gamida-cell.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.
Recent news